Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

Movement Disorders

Volumn 13, Issue 1, 1998, Pages 46-51

  Korczyn, Amos D ^a   Brooks, David J ^b   Brunt, Ehrout R ^c   Poewe, Warner H ^d   Rascol, Olivier ^e   Stocchi, Fabrizzio ^f  

^a TEL AVIV UNIVERSITY   (Israel)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bromocriptine; Dopamine agonist; Double blind, controlled study; Early Parkinson's disease; Ropinirole; Selegiline

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; ROPINIROLE; SELEGILINE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; VERTIGO; VOMITING;

ADULT; AGED; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; REGRESSION ANALYSIS; SELEGILINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0031975683     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130112     Document Type: Article

References (28)

1. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
2. Lees AJ. L-dopa treatment and Parkinson's disease. Q J Med 1986;59:535-547.
3. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995;45(suppl):231-238.
4. Rascol O. A double-blind L-dopa controlled study of ropinirole in patients with early Parkinson's disease [Abstract]. Neurology 1996;46(suppl):A160.
5. Wheadon DE, Wilson-Lynch K, Gardiner D, Kreider M. The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicentre, double-blind study [Abstract]. Neurology 1996;46(suppl):A159.
6. Rinne UK. Brief communication: early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
7. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-339.
8. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neural Neurosurg Psychiatry 1994;57:903-910.
9. Wolters ECh, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3): S28-S34.
10. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
11. Roos RAC, Vredevoogd CB, Van der Velde EA. Response fluctuations in Parkinson's disease. Neurology 1990;40:1344-1346.
12. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
13. Hely MA, Morris JGL, Rail D. The Sydney multicentre study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1989;53:324-328.
14. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995;310:575-579.
15. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-S12.
16. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-1014.
17. 2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
18. 2 agonist SK&F 101468. Lancet 1989;1:1445-1446.
19. Vidailhet MJ, Bonnet AM, Belal S, Dubois B, Marie C, Agid Y. Ropinirole without levodopa in Parkinson's disease [Letter]. Lancet 1990;336:316-317.
20. Kleedorfer B, Stern GM, Lees AJ, Bottomley JM, Sree-Haran N. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:10.
21. 2-receptor agonist. Br J Clin Pharmacol 1989;28:435-441.
22. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year L-dopa-controlled study. Mov Disord 1998;13:39-45.
23. Fahn S, Elton RL, et al. Unified Parkinson's Disease Rating Scale. In: Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
24. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale Motor Examination. Mov Disord 1994;9:89-91.
25. Guy W. ECDEU Assessment manual for psychopharmacology. Washington, DC: NIMH; 1976:217-222. DHEW Publ. No. (Adm.) 76-338.
26. Jackson DM, Jenkins OF, Ross SB. The motor effects of bromocriptine - a review. Psychopharmacology 1988;95:433-446.
27. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
28. Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de-novo patients with Parkinson's disease. A seven year follow-up. Acta Neurol Scand 1990;81:383-387.